Brain tumours are difficult to diagnose – 40% are found as emergency presentations, and long diagnostic journeys are common.
Dxcover’s proprietary PANAROMIC™ Platform can detect the presence of disease with minute volumes of liquid sample, with a turnaround time of one day. This technology goes beyond other liquid biopsy methods by harnessing the power of AI and utilising a multiomic spectral analysis (MOSA-Dx™), to improve early-stage detection of a range of solid tumours. The test result is designed to be a valuable tool for clinicians to make rapid and appropriate patient management decisions.
Professor Matthew Baker is CEO and President of Dxcover and as such is responsible for the direction, strategy, and operations of the company. He recognises the to the need to develop his leadership skills to support the scale up and translation of our technology to a new region. These areas will significantly impact Dxcover’s plan over the next 12 months.
Professor Baker is looking forward to the networking and training involved in the Shott Scale Up Accelerator to support scaling and expanding a deep tech company such as Dxcover. He particularly wants to use the training to enhance his leadership skills to support this. He also recognises the value of expanding his personal network within the scale up sphere with other founders and investors.
Dxcover were recipients of a 2.5 million Euro grant from the European Innovation Council to drive forward the translation of the platform, and particularly the Dxcover Brain Cancer Liquid Biopsy. They are now working to bring their Brain Cancer Liquid Biopsy to market and expand their offering into the US.